Age-related features of melatonin receptor expression in the cardiomyocytes of patients with dilated cardiomyopathy
DOI: https://doi.org/10.29296/25877305-2021-09-14
Issue:
9
Year:
2021
To understand the pathogenesis of dilated cardiomyopathy (DCM), it is necessary to establish the
molecular and cellular mechanisms of myocardial aging, including those associated with melatonin. The latter
affects vascular tone, the binding of smooth muscle cells and vascular endothelium to their own receptors
(melatonin receptor type 1A (MR1A), melatonin receptor 1B (MR1B)) and acts on the adrenergic and peptidergic
(vasointestinal peptide and substance P) endings of perivascular nerves, which allows melatonin to be
considered as an important predictor of the development of DCM. The molecular mechanisms of this interaction
still remain insufficiently studied. Objective: to study MR1A and MR1V in the cardiomyocytes of patients
with DCM in vitro. Methods. Primary dissociated cell cultures and immunofluorescence confocal laser scanning
microscopy were used. Passages 3 and 10 cells corresponding to young and old cultures were applied to model
cellular senescence. Results. At the molecular level, cardiomyocyte senescence was accompanied by a 3-fold
decrease in the level of MR1B expression compared to the old cultures in both the control and the DCM groups
(by 1.8 times). Furthermore, there was a 2-fold decrease in MR1A expression in the cell cultures taken from
patients with DCM compared with the similar culture of normal cardiomyocytes. The expression of MR1B was
significantly lower in the DCM group than that in the control group in passage 3. With aging in the
cultures, the level of MR1B expression was significantly lower by 3.9 times in the DCMP group than that in
the control group. The similar trends in the studied markers may suggest that both melatonin receptors are
involved in the pathogenesis of DCM, which may also be involved in the mechanisms of aging. The findings
will be able to expand the concept of DCM and to form its diagnostic panel in people of different ages.
Keywords:
geriatrics
cardiology
dilated cardiomyopathy
heart cellular senescence
melatonin receptors
cell culture
confocal microscopy
References:
- Anderson R., Lagnado A., Maggiorani D. et al. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. EMBO J. 2019; 38 (5): e100492. DOI: 10.15252/embj.2018100492
- Shimizu I., Minamino T. Cellular senescence in cardiac diseases. J Cardiol. 2019; 74 (4): 313–9. DOI: 10.1016/j.jjcc.2019.05.002
- McNally E.M., Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res. 2017; 121 (7): 731–48. DOI: 10.1161/CIRCRESAHA.116.309396
- Guzzo-Merello G., Cobo-Marcos M., Gallego-Delgado M. et al. Alcoholic cardiomyopathy. World J Cardiol. 2014; 6 (8): 771–81. DOI: 10.4330/wjc.v6.i8.771
- Schultheiss H.P., Fairweather D., Caforio A.L.P. et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019; 9 (5): 32. DOI: 10.1038/s41572-019-0084-1
- Anderson R., Richardson G.D., Passos J.F. Mechanisms driving the ageing heart. Exp Gerontol. 2018; 109: 5–15. DOI: 10.1016/j.exger.2017.10.015
- Pinto Y.M., Elliott P.M., Arbustini E. et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016; 37: 1850–8. DOI: 10.1093/eurheartj/ehv727
- Weintraub R.G., Semsarian C., Macdonald P. Dilated cardiomyopathy. Lancet. 2017; 390 (10092): 400–14. DOI: 10.1016/S0140-6736(16)31713-5
- Elliott P., Andersson B., Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29 (2): 270–6. DOI: 10.1093/eurheartj/ehm342
- Lopez-Otin C., Blasco M.A., Partridge L. et al. The hallmarks of aging. Cell. 2013; 153 (6): 1194–217. DOI: 10.1016/j.cell.2013.05.039
- Japp A.G., Gulati A., Cook S.A. et al. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016; 67 (25): 2996–3010. DOI: 10.1016/j.jacc.2016.03.590
- Merlo M., Cannatà A., Gobbo M. et al. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018; 20 (2): 228–39. DOI: 10.1002/ejhf.1103
- Kurganova Ju.M., Danilov A.B., Gorjachev D.V. Melatonin i bol'. Zhurnal nevrologii i psihiatrii im. SS. Korsakova. 2014; 114 (6): 31–7 [Kurganova Iu.M., Danilov A.B., Goriachev D.V. Melatonin and pain. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014; 114 (6): 31–7 (in Russ.)].
- Japp A.G., Gulati A., Cook S.A., et al. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016; 67 (25): 2996–3010. DOI: 10.1016/j.jacc.2016.03.590
- Rapoport S.I., Golichenkov V.A. Melatonin: teorija i praktika. M.: Medpraktika-M, 2009; 100 s. [Rapoport S.I., Golichenkov V.A. Melatonin: teoriya i praktika. M.: Medpraktika-M, 2009; 100 p. (in Russ.)].
- Arendt J., Bojkowski C., Folkard S. et al. Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp. 1985; 117: 266–83. DOI: 10.1002/9780470720981.ch16
- Arendt J. Melatonin in humans: it’s about time. J Neuroendocrinol. 2005; 17 (8): 537–8. DOI: 10.1111/j.1365-2826.2005.01333.x
- Vajhanskaja T.G., Sivitskaja L.N., Kurushko T.V. i dr. Dilatatsionnaja kardiomiopatija: novyj vzgljad na problemu. Rossijskij kardiologicheskij zhurnal. 2019; 4: 35–47 [Vaykhanskaya T.G., Sivitskaya L.N., Kurushko T.V. et al. Dilated cardiomyopathy: reconceptualization of the problem. Russian Journal of Cardiology. 2019; 4: 35–47 (in Russ.)]. DOI: 10.15829/1560-4071-2019-4-35-47